L'Oréal has launched L'Oréal Act for Dermatology, a five-year skin health program with an investment of 20 million euros, under its Dermatological Beauty Division. This initiative is carried out in collaboration with the World Health Organization (WHO) Foundation to support WHO's efforts in combating common skin diseases and those caused by neglected tropical diseases.
According to Myriam Cohen-Welgryn, President of L'Oréal Dermatological Beauty, the program reflects the company's commitment to improving the lives of billions of people who suffer the physical, mental, and emotional burden of skin diseases, addressing the challenges they face in accessing skin health services.
The program is based on four pillars:
-
Invest in research to deepen the understanding of skin health and the main barriers to accessing dermatological services.
-
Raise awareness in both public and private sectors about the importance of skin health.
-
Allocate 2 million euros to facilitate open access to scientific publications in low- and middle-income countries, with the aim of empowering health workers worldwide to diagnose and treat skin diseases.
-
Invest in a "do tank" to expand access to dermatological diagnosis and treatment.
The collaboration with the WHO Foundation will, for the first time, enable global surveillance of skin health, covering common diseases such as acne, atopic dermatitis, psoriasis, and vitiligo, as well as neglected tropical diseases related to the skin.
This initiative comes at a time of increasing recognition of skin health on the global health agenda, with the 78th World Health Assembly in May 2025 expected to discuss a resolution on skin diseases as a global public health priority.